Navigation Links
Scientists use worms to unearth cancer drug targets
Date:8/9/2012

BETHESDA, MD August 9, 2012 -- Through novel experiments involving small nematode worms, scientists from Wyoming have discovered several genes that may be potential targets for drug development in the ongoing war against cancer. Specifically, researchers hypothesize that inhibiting these genes could reverse certain key traits associated with cancer cells. This discovery is published in the August 2012 issue of the Genetics Society of America's journal GENETICS (www.genetics.org).

"Cancer is a leading cause of death worldwide," said David S. Fay, Ph.D., a researcher involved in the work from the Molecular Biology Department at the University of Wyoming in Laramie. "We hope that by carrying out basic genetic research on one of the most widely implicated human cancer genes, that we can contribute to the arsenal of diverse therapeutic approaches used to treat and cure many types of cancer."

To make this discovery, Dr. Fay and his colleagues used a strain of nematode worms that carried a mutation in a gene similar to one that is inactivated in many human cancers. This gene, called "LIN-35" in worms and "pRb" in humans, is thought to control at least several aspects of tumor progression including cancer cell growth and survival. The researchers systematically inactivated other individual genes in the genome of the mutant LIN-35 worms. As they deactivated various genes, scientists identified those that led to a reversal of defects caused by the loss of LIN-35, suggesting that they could be used as targets for anti-cancer therapies.

"This research is important because it offers possible new ways to shut down the genetic machinery that contributes to cancer growth and progression," said Mark Johnston, Ph.D., Editor-in-Chief of the journal GENETICS. "The causes of cancer are complex and varied, so we must approach this disease from many angles. Using simple 'model organisms,' such as nematode worms to find new drug targets, is becoming an increasingly important and effective strategy."

As a companion piece to this article, the journal GENETICS debuts a new educational resource called a Primer. The Primer article, written by Elizabeth A. De Stasio, Ph.D., of Lawrence University in Appleton, Wisconsin, provides guidelines for genetics instructors who want to use this contemporary research on nematode worms to teach their students about genetics concepts. The Primer includes background biological information on the worms, explanations of concepts used, and a sample approach to using the article in the classroom with questions for discussion. Additional Primers for instructional use will follow in future issues of GENETICS.


'/>"/>
Contact: Phyllis Edelman
pedelman@genetics-gsa.org
301-634-7302
Genetics Society of America
Source:Eurekalert

Related biology news :

1. Composite nanofibers developed by Penn scientists next chapter in orthopaedic biomaterials
2. Scientists define new limits of microbial life in undersea volcanoes
3. Farmers team with scientists to make the perfect rat trap
4. Scientists discover molecular link between circadian clock disturbances and inflammatory diseases
5. UTMB scientists awarded NIH grant for lab-grown lung tissue project
6. WHOI scientists/engineers partner with companies to market revolutionary new instruments
7. Stanford-Penn State scientists use microbes to make clean methane
8. Citizen scientists needed for SF States ZomBee Watch
9. Scientists confirm existence of vitamin deserts in the ocean
10. MBL scientists to explore hidden realm of microbes, viruses beneath the ocean floor
11. Scientists connect seawater chemistry with climate change and evolution
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/12/2016)... WearablesResearch.com , a brand of Troubadour ... from the Q1 wave of its quarterly wearables survey. ... receptivity to a program where they would receive discounts ... company. "We were surprised to see that ... LaColla , CEO of Troubadour Research, "primarily because there ...
(Date:4/28/2016)... 2016 First quarter 2016:   ... with the first quarter of 2015 The gross margin ... (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... unchanged, SEK 7,000-8,500 M. The operating margin for 2016 ...
(Date:4/15/2016)...  A new partnership announced today will help ... in a fraction of the time it takes ... life insurance policies to consumers without requiring inconvenient ... Diagnostics, rapid testing (A1C, Cotinine and HIV) and ... weight, pulse, BMI, and activity data) available at ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... today announced the launch of the Supplyframe Design Lab . Located in ... to explore the future of how hardware projects are designed, built and brought ...
(Date:6/23/2016)... ... ... In a new case report published today in STEM CELLS Translational Medicine, doctors ... being treated for breast cancer benefitted from an injection of stem cells derived from ... frequent side effect of cancer treatment. , Lymphedema refers to the swelling ...
(Date:6/23/2016)...  Blueprint Bio, a company dedicated to identifying, protecting ... has closed its Series A funding round, according to ... "We have received a commitment from Forentis Fund that ... meet our current goals," stated Matthew Nunez . ... complete validation on the current projects in our pipeline, ...
(Date:6/23/2016)... , June 23, 2016 On ... session at 4,833.32, down 0.22%; the Dow Jones Industrial Average ... 500 closed at 2,085.45, down 0.17%. Stock-Callers.com has initiated coverage ... INFI ), Nektar Therapeutics (NASDAQ: NKTR ), Aralez ... Inc. (NASDAQ: BIND ). Learn more about these ...
Breaking Biology Technology: